Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/22754
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMeriç, Meliha-
dc.contributor.authorWillke, Ayse-
dc.contributor.authorFinke, Ernst-Jurgen-
dc.contributor.authorGrunow, Roland-
dc.contributor.authorSayan, Murat-
dc.contributor.authorErdoğan, Sarper-
dc.date.accessioned2021-11-22T11:19:55Z-
dc.date.available2021-11-22T11:19:55Z-
dc.date.issued2008-01-
dc.identifier.citationMeriç, M. vd. (2008). ''Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia''. Apmis, 116(1), 66-73.en_US
dc.identifier.issn0903-4641-
dc.identifier.urihttps://doi.org/10.1111/j.1600-0463.2008.00901.x-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1600-0463.2008.00901.x-
dc.identifier.urihttp://hdl.handle.net/11452/22754-
dc.description.abstractTularemia outbreaks have occurred in various regions of Turkey in recent years. In this study, clinical (145 patients) and laboratory (97 patients) features of patients with oropharyngeal tularemia were evaluated during the tularemia outbreak in the district of Golcuk in Kocaeli, Turkey. We analyzed the risk factors for therapeutic failure and prolonged recovery time, and compared the efficacy of three antibiotic groups, namely aminoglycoside, tetracycline and quinolone. The most common physical sign and laboratory findings in patients were lymphadenopathy (LAP) and increased erythrocyte sedimentation rate, respectively. Treatment failure was observed in 55 of the 145 (38%) patients during one-year follow-up and the most successful results were obtained in the quinolone group. It was determined that antimicrobial therapy initiated 14 days after onset of symptoms was a statistically significiant risk factor, reducing the success rate (p=0.0001, OR=13.10, 95% CI=5.69-30.15) and prolonging the recovery period (p=0.001, OR=3.23, 95% CI=1.63-6.40) in oropharyngeal tularemia cases. These results suggest that antimicrobial treatment should be started early, and quinolones such as moxifloxacin and ciprofloxacin seem to be new alternatives in the treatment of oropharyngeal tularemia.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOropharyngeal tularemiaen_US
dc.subjectQuinolonesen_US
dc.subjectRisk factorsen_US
dc.subjectTherapeutic failureen_US
dc.subjectFrancisella-tularensisen_US
dc.subjectCiprofloxacinen_US
dc.subjectSusceptibilityen_US
dc.subjectFluoroquinolonesen_US
dc.subjectChildrenen_US
dc.subjectTurkeyen_US
dc.subjectImmunologyen_US
dc.subjectMicrobiologyen_US
dc.subjectPathologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAnti-Bacterial agentsen_US
dc.subject.meshBlood sedimentationen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDisease outbreaksen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLymphatic diseasesen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPharyngitisen_US
dc.subject.meshQuinolonesen_US
dc.subject.meshRisk factorsen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTularemiaen_US
dc.subject.meshTurkeyen_US
dc.titleEvaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: The role of quinolones in oropharyngeal tularemiaen_US
dc.typeArticleen_US
dc.identifier.wos000252805500010tr_TR
dc.identifier.scopus2-s2.0-38849182885tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.tr_TR
dc.identifier.startpage66tr_TR
dc.identifier.endpage73tr_TR
dc.identifier.volume116tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalApmisen_US
dc.contributor.buuauthorGedikoğlu, Suna-
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.identifier.pubmed18254782tr_TR
dc.subject.wosImmunologyen_US
dc.subject.wosMicrobiologyen_US
dc.subject.wosPathologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ4en_US
dc.wos.quartileQ3 (Pathology)en_US
dc.contributor.scopusid6603407548en_US
dc.subject.scopusFrancisella Tularensis; Tularemia; Tick Bitesen_US
dc.subject.emtreeAminoglycoside antibiotic agenten_US
dc.subject.emtreeCiprofloxacinen_US
dc.subject.emtreeDoxycyclineen_US
dc.subject.emtreeGentamicinen_US
dc.subject.emtreeMoxifloxacinen_US
dc.subject.emtreeQuinoline derived antiinfective agenten_US
dc.subject.emtreeStreptomycinen_US
dc.subject.emtreeTetracyclineen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAntimicrobial therapyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeConvalescenceen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeEpidemicen_US
dc.subject.emtreeErythrocyte sedimentation rateen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreelymphadenopathy;en_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOropharyngeal tularemiaen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeStatistical significanceen_US
dc.subject.emtreeTreatment failureen_US
dc.subject.emtreeTularemiaen_US
dc.subject.emtreeTurkey (republic)en_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.